WuXi PharmaTech (药明康德) announced it will discontinue its US-based biologics manufacturing business, which is currently operating out of its Philadelphia facility. The operation was part of WuXi’s controversial AppTec acquisition, completed earlier this year. In a conference call, WuXi management said the dynamics of the business have changed dramatically in the last three to six months. More details...

Stock Symbol: (NYSE: WX)